Genomics and new targets for multiple sclerosis
Related Experiment Video
Updated: Aug 18, 2026

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
Published on: December 1, 2023
Sergio E Baranzini1, Jorge R Oksenberg
1University of California, Department of Neurology, School of Medicine, San Francisco, CA 94143-0435, USA.
Abstract:
Compelling epidemiological and molecular data indicate that genes play a primary role in determining who is at risk for developing multiple sclerosis (MS), how the disease progresses, and how MS individuals respond to therapy. The genetic component of MS etiology is believed to result from the action of allelic variants in several genes. Their incomplete penetrance and moderate individual effect probably reflects epistatic interactions, post-transcriptional regulatory mechanisms, and environmental influences. Equally significant, it is likely that locus heterogeneity exists, whereby specific genes influence susceptibility and pathogenesis in some individuals but not in others.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Multiple Sclerosis l: Introduction
Genomics
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics and Pharmacogenomics: Overview